New drug delivery system to improve cancer treatment
Gold nanoparticles use DNA to deliver anti-cancer drug
Preliminary tests indicate that this delivery device has the potential to improve the results of cancer chemotherapy. DOX is currently used against cancers of the breast, bone marrow, thyroid, bladder, ovary, small cell lung and several others.
‘The possibilities of this new system are really exciting,’ said Professor James Dabrowiak at Syracuse University. ‘It would be easy to add to the device molecules that have the ability to target cancer cells. Another possibility is using light excitation to release high concentrations of an anti-tumour drug directly within the tumour.’
These and other upgrades could enable doctors to focus chemotherapy more tightly on cancer cells and reduce side effects on healthy cells in other parts of the body.
A key element of the system is that the DNA attached to the gold particles is engineered to bind to the DOX drug. Studies show that DOX can be transferred by diffusion to a receptor DNA molecule.
The gold nanoparticles have an average diameter of only 15.5nm or a few billionths of a metre. A single nanoparticle presents more than 100 DOX sites and that, when multiplied by millions of particles, could create a massive assault on a tumour, the researchers have found.
‘We believe this work can bring significant gains in the effectiveness of chemotherapy treatments,’ said Mathew Maye, Assistant Professor of Chemistry at Syracuse University and co-inventor of the delivery system. ‘We still have work to do but this advance opens a promising new field of investigation that can lead to important new clinical tools.’
The US FDA has already approved DOX. Other such drugs may be deployed using this system simply by engineering the DNA to bind to a different drug molecule.
The Syracuse researchers are continuing investigations to check the toxicity of the system. They will also explore ‘smart’ particles capable of attaching to cancer cells and responding to triggers that will activate drug release.
The work of the Syracuse team is published in a February 2011 issue of ChemComm, published by the Royal Society of Chemistry.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage
etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Drug Delivery
embecta completes £100m acquisition of UK-based Owen Mumford to bolster drug delivery portfolio
US diabetes care company embecta has finalised its acquisition of Owen Mumford, gaining access to the Aidaptus next-generation auto-injector platform as it accelerates its transition into a broad-based medical supplies company
Pharmaceutical
MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients
The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Drug Delivery
Wearable pumps and subcutaneous delivery: a new frontier in heart failure management
Two recent developments are reshaping how drug delivery technology can move treatment out of the clinic and into patients’ everyday lives — with implications for both formulation science and device manufacturing